Why Dendreon (DNDN) Stock Hit a One-Year Low Today

NEW YORK (TheStreet) -- Dendreon  (DNDN) plunged to a 52-week low of $1.33 on Tuesday after the company warned of "significant risk" it would not be able to pay its debt that matures in 2016, according to the biotech company's latest 10-Q filing.

"Accordingly, we are currently considering alternatives to the repayment of the 2016 Notes in cash, including alternatives that could result in leaving our current stockholders with little or no financial ownership of Dendreon," the company said in the filing.

For more on this story, read TheStreet's Adam Feuerstein's article here.

Must Read: Dendreon Warns Debt Bomb Might Wipe Out Shareholders

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

The stock was down 32.08% to $1.44 at 10:01 a.m. More than 7.6 million shares had changed hands, compared to the average volume of 1,969,290.

DNDN Chart DNDN data by YCharts

EXCLUSIVE OFFER: See inside Jim Cramer’s multi-million dollar charitable trust portfolio to see the stocks he and Stephanie Link think could be potentially HUGE winners. Click here to see the holdings for FREE.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

If you liked this article you might like

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Where Are They Now? A Look Back at the Best & Worst Biotech CEOs

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes

Stock Market Today: S&P 500 Eyes Strong Finish for 2014; Alibaba Spikes